Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.

Literature DB >> 26819050

Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.

David E Spaner¹, Guizhei Wang², Lindsay McCaw², Yanmei Li², Patricia Disperati³, Mary-Ann Cussen⁴, Yonghong Shi².

Abstract

Entities: Chemical Disease

Keywords: Ibrutinib; Janus Kinases; Kinase inhibitors; Ruxolitinib; STAT3; chronic lymphocytic leukemia; phosphoproteome

Mesh：

Substances：

Year: 2016 PMID： 26819050 PMCID： PMC5004376 DOI： 10.3324/haematol.2015.135418

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

14 in total

1. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

Authors: Annkristin Heine; Peter Brossart; Dominik Wolf
Journal: Blood Date: 2013-11-28 Impact factor: 22.113

2. Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A.

Authors: Yanmei Li; Yonghong Shi; Lindsay McCaw; You-Jun Li; Fang Zhu; Reg Gorczynski; Gordon S Duncan; Burton Yang; Yaacov Ben-David; David E Spaner
Journal: Blood Date: 2015-06-03 Impact factor: 22.113

Review 3. Targeted therapies in CLL: mechanisms of resistance and strategies for management.

Authors: Jennifer A Woyach; Amy J Johnson
Journal: Blood Date: 2015-06-11 Impact factor: 22.113

4. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.

Authors: Alireza Eghtedar; Srdan Verstovsek; Zeev Estrov; Jan Burger; Jorge Cortes; Carol Bivins; Stefan Faderl; Alessandra Ferrajoli; Gautam Borthakur; Solly George; Peggy A Scherle; Robert C Newton; Hagop M Kantarjian; Farhad Ravandi
Journal: Blood Date: 2012-03-15 Impact factor: 22.113

5. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors: Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245

6. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

Authors: Susan O'Brien; Richard R Furman; Steven E Coutre; Jeff P Sharman; Jan A Burger; Kristie A Blum; Barbara Grant; Donald A Richards; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Raquel Izumi; Ahmed Hamdy; Betty Y Chang; Thorsten Graef; Fong Clow; Joseph J Buggy; Danelle F James; John C Byrd
Journal: Lancet Oncol Date: 2013-12-10 Impact factor: 41.316

7. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

Authors: John C Byrd; Richard R Furman; Steven E Coutre; Jan A Burger; Kristie A Blum; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Yun Shaw; Elizabeth Bilotti; Cathy Zhou; Danelle F James; Susan O'Brien
Journal: Blood Date: 2015-02-19 Impact factor: 22.113

8. The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment.

Authors: Andrew J Steele; Archibald G Prentice; Kate Cwynarski; A Victor Hoffbrand; Stephen M Hart; Mark W Lowdell; Edward R Samuel; R Gitendra Wickremasinghe
Journal: Blood Date: 2010-08-17 Impact factor: 22.113

9. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal: Blood Date: 2008-01-23 Impact factor: 22.113

10. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.

Authors: John M L Ebos; Christina R Lee; James G Christensen; Anthony J Mutsaers; Robert S Kerbel
Journal: Proc Natl Acad Sci U S A Date: 2007-10-17 Impact factor: 11.205

11 in total

1. PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells.

Authors: L Sun; Y Shi; G Wang; X Wang; S Zeng; S E Dunn; G D Fairn; Y-J Li; D E Spaner
Journal: Leukemia Date: 2017-05-30 Impact factor: 11.528

2. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.

Authors: Matthew D Blunt; Stefan Koehrer; Rachel C Dobson; Marta Larrayoz; Sarah Wilmore; Alice Hayman; Jack Parnell; Lindsay D Smith; Andrew Davies; Peter W M Johnson; Pamela B Conley; Anjali Pandey; Jonathan C Strefford; Freda K Stevenson; Graham Packham; Francesco Forconi; Greg P Coffey; Jan A Burger; Andrew J Steele
Journal: Clin Cancer Res Date: 2016-10-03 Impact factor: 12.531

3. Trisomy 21 consistently activates the interferon response.

Authors: Kelly D Sullivan; Hannah C Lewis; Amanda A Hill; Ahwan Pandey; Leisa P Jackson; Joseph M Cabral; Keith P Smith; L Alexander Liggett; Eliana B Gomez; Matthew D Galbraith; James DeGregori; Joaquín M Espinosa
Journal: Elife Date: 2016-07-29 Impact factor: 8.140

4. Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells.

Authors: Lindsay McCaw; Yonghong Shi; Guizhi Wang; You-Jun Li; David E Spaner
Journal: EBioMedicine Date: 2016-11-30 Impact factor: 8.143

5. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.

Authors: Preetesh Jain; Michael Keating; Sarah Renner; Charles Cleeland; Huang Xuelin; Graciela Nogueras Gonzalez; David Harris; Ping Li; Zhiming Liu; Ivo Veletic; Uri Rozovski; Nitin Jain; Phillip Thompson; Prithviraj Bose; Courtney DiNardo; Alessandra Ferrajoli; Susan O'Brien; Jan Burger; William Wierda; Srdan Verstovsek; Hagop Kantarjian; Zeev Estrov
Journal: Lancet Haematol Date: 2017-01-12 Impact factor: 18.959